Toshiyuki Sunaya Selected Research

Myocardial Infarction

6/2022	Impact of three major risk factors on clinical outcomes in patients with nonvalvular atrial fibrillation receiving rivaroxaban: Sub-analysis from the XAPASS study.
8/2020	Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation.
12/2019	Real-world outcomes of rivaroxaban treatment in patients with nonvalvular atrial fibrillation and worsening renal function.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Toshiyuki Sunaya Research Topics

Disease

10	Hemorrhage 01/2023 - 07/2019
9	Atrial Fibrillation 06/2022 - 01/2019
6	Stroke (Strokes) 06/2022 - 01/2019
5	Embolism (Embolus) 06/2022 - 07/2019
4	Renal Cell Carcinoma (Grawitz Tumor) 04/2022 - 10/2015
3	Macular Edema 01/2023 - 01/2022
3	Myocardial Infarction 06/2022 - 12/2019
3	Body Weight (Weight, Body) 06/2022 - 11/2018
2	Thyroid Neoplasms (Thyroid Cancer) 09/2023 - 01/2022
2	Pulmonary Embolism 01/2023 - 10/2021
2	Venous Thromboembolism 01/2023 - 10/2021
2	Venous Thrombosis (Deep-Vein Thrombosis) 01/2023 - 10/2021
2	Neoplasms (Cancer) 01/2023 - 10/2016
2	Menorrhagia 12/2022 - 08/2022
2	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 10/2016
2	Neoplasm Metastasis (Metastasis) 04/2021 - 01/2021
2	Prostatic Neoplasms (Prostate Cancer) 04/2021 - 01/2021
2	Hypertension (High Blood Pressure) 03/2020 - 10/2015
2	Colorectal Neoplasms (Colorectal Cancer) 01/2019 - 01/2018
2	Drug-Related Side Effects and Adverse Reactions 01/2018 - 10/2015
1	Macular Degeneration (Age-Related Maculopathy) 01/2023
1	Cerebral Infarction 01/2023
1	Dysmenorrhea (Menstrual Pain) 12/2022
1	Chronic Renal Insufficiency 01/2022
1	Proteinuria 01/2022
1	Retinal Vein Occlusion 01/2022
1	Vascular Diseases (Vascular Disease) 01/2021
1	Diabetes Mellitus 01/2021
1	Pulmonary Hypertension 07/2020
1	Thromboembolism 04/2020
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2020
1	Transient Ischemic Attack 01/2019
1	Ischemic Stroke 01/2019
1	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2018
1	Hepatitis C 10/2016
1	Exanthema (Rash) 10/2015

Drug/Important Bio-Agent (IBA)

11	RivaroxabanIBA 01/2023 - 01/2019
7	CreatinineIBA 01/2023 - 01/2019
6	Sorafenib (BAY 43-9006)FDA Link 09/2023 - 10/2015
4	afliberceptIBA 01/2023 - 01/2022
4	AnticoagulantsIBA 04/2020 - 11/2019
2	Factor Xa InhibitorsIBA 01/2023 - 07/2019
2	Levonorgestrel (Plan B)FDA LinkGeneric 12/2022 - 08/2022
2	Radium-223IBA 04/2021 - 01/2021
2	regorafenibIBA 01/2019 - 01/2018
1	Retinaldehyde (Retinal)IBA 01/2023
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2022
1	Androgen Receptors (Androgen Receptor)IBA 04/2021
1	Prostate-Specific Antigen (Semenogelase)IBA 04/2021
1	Analgesics (Analgesic Drugs)IBA 04/2021
1	riociguatIBA 07/2020
1	gadobutrolIBA 11/2018
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 10/2016
1	Hemoglobins (Hemoglobin)IBA 10/2016
1	Lipase (Acid Lipase)FDA Link 10/2015
1	Amylases FDA Link 10/2015

Therapy/Procedure

3	Drug Therapy (Chemotherapy) 04/2021 - 01/2019
2	Castration 04/2021 - 01/2021
2	Therapeutics 01/2019 - 10/2015